New drug RAY121 tested for Long-Term safety in autoimmune patients
Disease control
ENROLLING_BY_INVITATION
This study looks at the long-term safety of a drug called RAY121 in people with certain immune system diseases, such as antiphospholipid syndrome, bullous pemphigoid, and immune thrombocytopenia. About 144 participants who have already received four doses of RAY121 in a previous …
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 02:25 UTC